Discovery of (S)-3-(3-(3,5-Dimethyl-1H-pyrazol-1-yl)phenyl)-4-((R)-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)pyrrolidin-1-yl)butanoic Acid, a Nonpeptidic αvβ6 Integrin Inhibitor for the Inhaled Treatment of Idiopathic Pulmonary Fibrosis
Authors:
- Panayiotis A. ProcopiouPPPanayiotis A. Procopiou
- Niall A. AndersonNANiall A. Anderson
- John BarrettJBJohn Barrett
- Tim N. BarrettTBTim N. Barrett
- Matthew H. J. CrawfordMCMatthew H. J. Crawford
- Brendan J. FallonBFBrendan J. Fallon
- Ashley P. HancockAHAshley P. Hancock
- Joelle LeJLJoelle Le
- Seble LemmaSLSeble Lemma
- Richard P. MarshallRMRichard P. Marshall
- Josie MorrellJMJosie Morrell
- John M. PritchardJPJohn M. Pritchard
- 14 September 2018
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 61 (18) , 8417-8443
Abstract
A series of 3-aryl(pyrrolidin-1-yl)butanoic acids were synthesized using a diastereoselective route, via a rhodium catalyzed asymmetric 1,4-addition of arylboronic acids in the presence of (R)-BINAP to a crotonate ester to provide the (S) absolute configuration for the major product. A variety of aryl substituents including morpholine, pyrazole, triazole, imidazole, and cyclic ether were screened in cell adhesion assays for affinity against αvβ1, αvβ3, αvβ5, αvβ6, and αvβ8 integrins. Numerous analogs with high affinity and selectivity for the αvβ6 integrin were identified. The analog (S)-3-(3-(3,5-dimethyl-1H-pyrazol-1-yl)phenyl)-4-((R)-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)pyrrolidin-1-yl)butanoic acid hydrochloride salt was found to have very high affinity for αvβ6 integrin in a radioligand binding assay (pKi = 11), a long dissociation half-life (7 h), very high solubility in saline at pH 7 (>71 mg/mL), and pharmacokinetic properties commensurate with inhaled dosing by nebulization. It was selected for further clinical investigation as a potential therapeutic agent for the treatment of idiopathic pulmonary fibrosis.Keywords
This publication has 54 references indexed in Scilit:
- M30 Effect of dose reductions and/or interruptions on the efficacy of nintedanib in patients with idiopathic pulmonary fibrosis (ipf): subgroup analysis of the inpulsis trials2017
- Idiopathic pulmonary fibrosis: Clinical behavior and aging associated comorbiditiesRespiratory Medicine, 2017
- Current approaches to the management of idiopathic pulmonary fibrosisRespiratory Medicine, 2017
- Idiopathic pulmonary fibrosisThe Lancet, 2017
- Integrin-based therapeutics: biological basis, clinical use and new drugsNature Reviews Drug Discovery, 2016
- Dissecting fibrosis: therapeutic insights from the small-molecule toolboxNature Reviews Drug Discovery, 2015
- Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic reviewEuropean Respiratory Journal, 2015
- A consensus document for the selection of lung transplant candidates: 2014—An update from the Pulmonary Transplantation Council of the International Society for Heart and Lung TransplantationThe Journal of Heart and Lung Transplantation, 2015
- Novel therapeutic approaches for pulmonary fibrosisBritish Journal of Pharmacology, 2011
- IntegrinsCell and tissue research, 2009